

East of England - Cambridge East Research Ethics Committee

The Old Chapel
Royal Standard Place
Nottingham
NG1 6FS

**Please note: This is the
favourable opinion of the REC
only and does not allow the
amendment to be implemented
at NHS sites in England until
the outcome of the HRA
assessment has been
confirmed.**

24 March 2020

Peter Horby
University of Oxford
New Richards Building, Old Road Campus, Headington
Oxford
OX3 7LG

Dear Horby

Study title:	Randomised Evaluation of COVID-19 Therapy (RECOVERY)
REC reference:	20/EE/0101
Protocol number:	NDPHRECOVERY
EudraCT number:	2020-001113-21
Amendment number:	Substantial Amendment 1
Amendment date:	20 March 2020
IRAS project ID:	281712

The above amendment was reviewed by the Sub-Committee in correspondence.

Ethical opinion

The members of the Committee taking part in the review gave a favourable ethical opinion of the amendment on the basis described in the notice of amendment form and supporting documentation.

Approved documents

The documents reviewed and approved at the meeting were:

<i>Document</i>	<i>Version</i>	<i>Date</i>
Annex 2: Notification of Amendment	Substantial Amendment 1	20 March 2020
Covering letter on headed paper		23 March 2020
Other [Sponsor approval]		23 March 2020
Other [PIS+ICF (clean)]	2.0	23 March 2020
Other [Hydroxychloroquine SmPC]		21 March 2020
Other [PIS+ICF (TC)]	2.0	23 March 2020
Protocol [clean]	2.0	23 March 2020
Protocol [tracked changes]	2.0	23 March 2020

Membership of the Committee

The members of the Committee who took part in the review are listed on the attached sheet.

Working with NHS Care Organisations

Sponsors should ensure that they notify the R&D office for the relevant NHS care organisation of this amendment in line with the terms detailed in the categorisation email issued by the lead nation for the study.

Statement of compliance

This Committee is recognised by the United Kingdom Ethics Committee Authority under the Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the ethical review of clinical trials of investigational medicinal products.

The Committee is fully compliant with the Regulations as they relate to ethics committees and the conditions and principles of good clinical practice.

The Committee is constituted in accordance with the Governance Arrangements for Research Ethics Committees and complies fully with the Standard Operating Procedures for Research Ethics Committees in the UK.

HRA Learning

We are pleased to welcome researchers and research staff to our HRA Learning Events and online learning opportunities– see details at: <https://www.hra.nhs.uk/planning-and-improving-research/learning/>

20/EE/0101:	Please quote this number on all correspondence
--------------------	---

Yours sincerely



Dr Alan Lamont
Chair

E-mail: CambridgeEast.REC@hra.nhs.uk

*Enclosures: List of names and professions of members who took part in the
review*

Copy to: NA NA CTRG

East of England - Cambridge East Research Ethics Committee

Attendance at Sub-Committee of the REC meeting on 24 March 2020

Committee Members:

<i>Name</i>	<i>Profession</i>	<i>Present</i>	<i>Notes</i>
Dr Philip Bedford	Retired Study Responsible Scientist	Yes	
Dr Alan Lamont/Chair	Retired Consultant Oncologist	Yes	

Also in attendance:

<i>Name</i>	<i>Position (or reason for attending)</i>
Miss Joy Uzoma	